Biosimilars, also known as "follow-on biologics," "similar biologics" or "biogenerics," are the generic versions of biologic drugs. They are important biotherapeutic drugs that are used for the treatment of several serious and debilitating diseases. Most of the innovator biologics are billion-dollar drugs and have a sizeable share of the biopharmaceuticals market. The high cost associated with the biologics has created a situation of limited access for millions of patients around the globe, and in particular, in emerging countries. The patent expirations of the blockbuster drugs have led to a growing interest in the development of biosimilars. Biosimilars have the potential to allow wide and affordable access due to their lower cost.
For an inside look at the biosimilars market, BCC sat down with Professor Sarfaraz K. Niazi, a world-renowned expert in biopharmaceutical manufacturing and founder of Pharmaceutical Scientist, Inc., Karyo Biologics and Adello Biologics. Professor Niazi has developed biosimilar versions of filgrastim, erythropoietin, interferon, Pegfilgrastim, adalimumab and other monoclonal antibodies.
Continue reading this report plus more!
Monthly Access $9.99
Single Paper $59.99